Abiraterone Clinical Trials
19 recruitingDrug
Phase 211Phase 17Phase 35
Showing 1–19 of 19 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled11 locationsNCT07226986
Recruiting
Phase 2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals150 enrolled65 locationsNCT06991556
Recruiting
Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled75 locationsNCT06863272
Recruiting
Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Canadian Cancer Trials Group830 enrolled340 locationsNCT06592924
Recruiting
Phase 2
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
Prostate Cancer
University of Nebraska140 enrolled1 locationNCT07237269
Recruiting
Phase 1
SNV1521 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Synnovation Therapeutics, Inc.400 enrolled21 locationsNCT06220864
Recruiting
Phase 1Phase 2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals155 enrolled22 locationsNCT07190300
Recruiting
Phase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Hoffmann-La Roche100 enrolled13 locationsNCT07287150
Recruiting
Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Amgen479 enrolled57 locationsNCT04221542
Recruiting
Phase 2
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Prostate CancerMetastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute26 enrolled2 locationsNCT05751941
Recruiting
Phase 2
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Advanced Prostate Adenocarcinoma
University of California, Davis75 enrolled1 locationNCT06173362
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 1
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen60 enrolled11 locationsNCT07140900
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 2
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Prostate Adenocarcinoma
University of Washington100 enrolled2 locationsNCT04175431
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumors
DualityBio Inc.862 enrolled107 locationsNCT05914116
Recruiting
Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+2 more
SWOG Cancer Research Network1,273 enrolled338 locationsNCT03678025
Recruiting
Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited430 enrolled15 locationsNCT06520345